Answers are grounded in this paper and cite their sources.
OBJECTIVE: Methylphenidate (MPH) has been a cornerstone of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy for more than 70 years, with robust evidence supporting its efficacy and tolerability across the patient lifespan. Despite this extensive evidence base, persistent myths and misconceptions among clinicians, patients, and caregivers continue to drive treatment hesitancy, premature discontinuation, and suboptimal prescribing practices. Our objective was to identify and critically appraise prevalent myths surrounding MPH use in ADHD that may adversely influence treatment decisions. METHODS: Myths were identified based on clinical experience, discussions with prominent ADHD experts, and a literature search for relevant articles and guidelines. Evidence from the literature was reviewed and supplemented with clinical recommendations. RESULTS: Twelve common misconceptions about MPH were identified. These include misconceptions about interchangeability and dose equivalence between MPH formulations, treatment timing for continuous symptom control, endurance of drug onset- and offset-related side effects, and patient feelings as an indicator of drug effectiveness. Myths that MPH will always cause insomnia, increase anxiety and depression, stunt growth, have similar levels of abuse potential and side effects as other drugs, or worsen behavior in patients with autism spectrum disorder were also identified, as well as a common misconception that MPH is only effective in child and adolescent populations. Evidence gathered from systematic reviews, meta-analyses, clinical trials, pharmacokinetic studies, and clinical practice guidelines provided counterarguments to these concerns. CONCLUSIONS: MPH remains a well-studied, effective, and generally well-tolerated treatment for ADHD in children, adolescents, and adults. The diversity of available formulations, including novel delivery systems such as delayed-release/extended-release MPH and serdexmethylphenidate/dexmethylphenidate, allows for individualized treatment matched to patient needs and daily functional demands. Clinicians who understand evidence-based rebuttals to myths about MPH can improve prescribing decisions and patient/family counseling while reducing the burden of misinformation that contributes to the undertreatment of this highly prevalent neurodevelopmental disorder.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: